Health Care
Leading the Cause
Zimmer led the push for MIS joint replacements as well. But Zimmer's breakthrough surgery technique -- the two-incision hip replacement -- proved too challenging for widespread adoption and, therefore, fell short of the company's revolutionary aims. Today, only 6% to 7% of surgeons who use Zimmer implants rely on the complicated procedure. To be fair, most Zimmer surgeons have wound up adopting other company-sponsored MIS procedures instead. But critics still question the soundness of MIS joint replacements, due to possible complications, and even Zimmer's focus on that particular niche. After all, they note, Zimmer has basically spent a whole lot of money training surgeons to use the same old devices in a different way. "All of these things -- MIS, computer-assisted surgery, gender-specific knees, etc. -- are costly extensions for Zimmer and the others," says a former sales manager who has marketed orthopedic devices for several major players in the past. But "none of these products are actually changing market share. It's just a big 'keep up with the Joneses' game that is costing these companies more money and slowing down the process of replacing joints." Still, Zimmer clearly feels otherwise. "We devote huge energy to innovative game-breakers -- whether it's MIS or Gender Solutions or high-flexion -- and we focus a lot of dollars there," Elliott admitted last month. "We're having a lot of fun with (Gender Solutions), and there actually is some great science to it. ... It will make for some unique debate in case anybody was getting bored listening to orthopedics."TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,419.86 | 1,313.32 | 2,837.36 | 15.95 |
Oil *
102.95
|
|
DOWN
160.83 |
DOWN
19.10 |
DOWN
33.63 |
DOWN
0.30 |
10 Yr
1.60%
SPDR Gold
151.91
|
|
-1.28%
|
-1.43%
|
-1.17%
|
-1.85%
|
Data delayed 20 minutes |


Connect with TheStreet